ADC Therapeutics Strategy and Business Model

Executive Overview

ADC Therapeutics is a commercial-stage oncology biotechnology company focused on antibody drug conjugates, or ADCs, for hematologic malignancies and selected solid tumors. Founded in 2011 and headquartered in Epalinges, Switzerland, the company combines a Swiss corporate base with a largely U.S.-focused commercial model. Its current revenue base is centered on Zynlonta, its CD19-directed ADC for relapsed or refractory large B-cell lymphoma, while the broader investment case depends on whether it can turn one approved product into a repeatable ADC platform business. As of FY2023, ADC Therapeutics generated roughly $70 million of revenue, which means strategy is shaped as much by capital discipline as by scientific ambition.

In practical terms, ADC Therapeutics is trying to do three things at once. First, it needs to grow and defend Zynlonta in an increasingly crowded lymphoma treatment landscape that includes bispecific antibodies and chimeric antigen receptor T-cell, or CAR-T, therapies. Second, it needs to generate the clinical evidence required to broaden Zynlonta’s role and support its regulatory position. Third, it must advance selected pipeline candidates without taking on a cost structure that its current revenue base cannot support. That combination makes ADC Therapeutics a useful case study in how a small oncology company balances science, commercialization, partnering, and cash runway.

ADC Therapeutics at a Glance

Logo
Common name	ADC Therapeutics
Full legal name	ADC Therapeutics SA
Headquarters	Epalinges, Switzerland
Ownership	Publicly traded; NYSE-listed and widely held by public shareholders
Ticker	ADCT
Exchange	NYSE - New York Stock Exchange
Market Cap	$146.27M
Revenue (FY2024)	#N/A
Founding / major historical milestones	Founded in 2011; initial public offering in 2020; U.S. approval of Zynlonta in 2021
Industry or industries	Biotechnology; oncology therapeutics; antibody drug conjugates
Key products or services	Zynlonta; clinical-stage ADC pipeline; licensing and partnering of regional rights
Geographic footprint	Corporate and development presence in Switzerland, the United States, and the United Kingdom; commercial revenue concentrated in the U.S.; additional international reach through partners
Business segments as officially reported	One operating and reportable segment
Company website	https://www.adctherapeutics.com/

1. What Is the Strategy of ADC Therapeutics?

Grounded in the company’s FY2023 annual report and 2024 earnings and investor communications, ADC Therapeutics’ strategy can be understood as an effort to become a durable ADC-focused oncology company rather than remain a single-product niche biotech. The company’s choices fit well into the Playing to Win framework.

1a. What is the winning aspiration of ADC Therapeutics?

ADC Therapeutics’ winning aspiration is to improve outcomes for patients with difficult-to-treat cancers by developing and commercializing differentiated ADCs, while building enough commercial and financial durability to support a broader oncology pipeline. In practice, “winning” currently means three things: sustaining Zynlonta as a meaningful product in large B-cell lymphoma, generating evidence that can expand its role, and advancing additional ADC candidates without compromising balance-sheet viability. The company has not emphasized a long-term public revenue target in the way large pharmaceutical companies sometimes do; its nearer-term measurable goals have instead centered on product uptake, clinical milestones, and cash runway.
1b. Where does ADC Therapeutics play?

ADC Therapeutics plays in oncology, with its clearest commercial focus in hematologic malignancies and a secondary development focus in selected solid tumors. Commercially, its current center of gravity is the U.S. market for relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma. Geographically, the company has chosen not to build a fully global sales footprint on its own balance sheet; instead, it combines direct activity in the U.S. with partner-led commercialization in other territories where available. From a modality standpoint, it is deliberately concentrated in ADCs rather than trying to compete across every oncology technology class.
1c. How does ADC Therapeutics plan to win?

ADC Therapeutics plans to win by offering targeted oncology medicines that are clinically differentiated enough to earn a place in fast-moving treatment pathways, while operating with more focus than a large diversified pharma company. For Zynlonta, that means positioning an off-the-shelf infused therapy for patients and treatment settings where speed, convenience, community-oncology usability, or post-CAR-T positioning may matter. More broadly, the company seeks to win through ADC design expertise, indication selection, and capital-efficient commercialization. The strategy is not to outspend larger rivals, but to be more selective in target choice, development sequencing, and partnering.
1d. What capabilities must ADC Therapeutics have in place?

To execute this strategy, ADC Therapeutics needs strong capabilities in translational oncology research, clinical development, regulatory strategy, chemistry-manufacturing-controls execution, pharmacovigilance, and specialty oncology commercialization. Because ADCs are complex products, manufacturing oversight and quality systems are as strategically important as discovery science. The company also needs disciplined business development and partner-management capabilities, since it relies on external relationships for manufacturing, clinical execution support, and international reach.
1e. What management systems does ADC Therapeutics require?

ADC Therapeutics needs management systems built around rigorous portfolio review, cash control, safety monitoring, and external-vendor governance. That includes stage-gate decision making on pipeline programs, tight oversight of clinical milestones, quality and release management across third-party manufacturing partners, and continuous post-marketing safety and reimbursement support for Zynlonta. In a small oncology company, management systems must do more than track progress; they must actively prevent capital from being spread too thinly across too many programs.

2. What Are the Current Strategic Initiatives of ADC Therapeutics?

As of the company’s FY2023 reporting and 2024 public updates, ADC Therapeutics’ strategic initiatives appear concentrated around a relatively small number of high-stakes priorities.

Drive Zynlonta adoption in its approved U.S. indication.Zynlonta is the company’s economic engine, so execution in relapsed or refractory large B-cell lymphoma remains central. This includes physician education, community-oncology penetration, reimbursement support, and maintaining clinical visibility in a market that is increasingly crowded with bispecific antibodies and cell therapies.
Generate confirmatory and label-expansion evidence for Zynlonta.ADC Therapeutics has publicly highlighted studies intended to support broader use of Zynlonta and strengthen its place in treatment algorithms. A key example is LOTIS-5, a randomized confirmatory study of Zynlonta plus rituximab versus an immunochemotherapy comparator in relapsed or refractory diffuse large B-cell lymphoma. Another visible initiative has been LOTIS-7, which has explored Zynlonta in combination with glofitamab, reflecting management’s interest in combination regimens rather than relying only on single-agent use.
Advance selected pipeline assets while narrowing portfolio risk.Public disclosures indicate a more selective development posture. ADC Therapeutics has continued to discuss advancing wholly owned pipeline candidates such as ADCT-601, while also becoming more disciplined about which programs justify further investment. Camidanlumab tesirine had been a major late-stage asset, but safety-related regulatory issues made its path materially more complex, pushing the company toward sharper prioritization.
Use partnerships to extend geographic reach.Rather than build full commercial infrastructure across multiple regions, ADC Therapeutics has used regional partners to reach markets outside the U.S. This lowers fixed cost and can bring in upfront, milestone, or royalty streams, although it also gives the company less direct control over launch quality and market development.
Preserve liquidity and reduce strategic sprawl.Because ADC Therapeutics is still loss-making, financing discipline is itself a strategic initiative. Management has emphasized prioritizing programs with the best risk-adjusted return, controlling operating expense, and aligning development ambitions with available capital rather than assuming unrestricted access to new funding.

3. What Is the Business Model of ADC Therapeutics?

ADC Therapeutics has a classic commercial-stage biotech business model, but with an unusually sharp dependence on one product.

What customers actually buy:In the U.S., providers purchase Zynlonta for eligible patients with relapsed or refractory large B-cell lymphoma. Outside the U.S., the company can also monetize its assets through regional licensing and commercialization partnerships.
Recurring versus one-time revenue:Product revenue is repeat-driven but not recurring in the subscription sense. Each treated patient may receive multiple cycles, and new patients continually enter the addressable pool, but demand is still tied to patient flow and treatment duration. Partnering revenue is often lumpy, with upfront fees and milestones that do not repeat in a smooth pattern.
How pricing power works:Like other oncology drugs in areas of high unmet need, Zynlonta benefits from specialty-drug pricing and reimbursement frameworks. However, pricing power is constrained by payer management, treatment guidelines, and therapeutic alternatives such as bispecifics and CAR-T therapies. In practice, clinical relevance matters more than simple list-price flexibility.
Why the business mix matters:The mix between U.S. product sales and licensing revenue matters because it affects visibility and quality of earnings. Product sales can become a steadier commercial base if adoption grows, while licensing revenue can help finance development but tends to be episodic. With only one marketed product, the company’s revenue profile is inherently concentrated.
What drives gross margin, operating margin, and cash generation:Gross margin is shaped by outsourced manufacturing cost, scale utilization, royalties or obligations tied to underlying technology, and any inventory-related charges. Operating margin remains dominated by research and development and, to a lesser extent, specialty commercialization expense. Cash generation has remained negative because the cost of clinical development and maintaining an oncology infrastructure still exceeds current product revenue.
Revenue model:The revenue model is primarily specialty-drug sales in the U.S., supplemented by collaboration, milestone, and royalty-type revenue from partners. It is not a platform-software or service model; economically, it is a therapeutics model with a small but growing commercial component.

4. What Products and/or Services Does ADC Therapeutics Sell?

ADC Therapeutics sells oncology therapeutics, not broad healthcare services. Its offerings fall into three practical categories.

Zynlonta (loncastuximab tesirine-lpyl).This is the company’s flagship and only marketed product. In the U.S., it is approved for certain adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. It is currently the company’s most important product by revenue, strategic relevance, and investor importance.
Clinical-stage ADC pipeline.ADC Therapeutics has developed and advanced additional ADC candidates beyond Zynlonta. As of 2024, public materials continued to reference assets such as camidanlumab tesirine and ADCT-601, among others, although the company had become more selective about which programs to prioritize. These programs do not yet drive material revenue, but they are central to the company’s long-term value proposition.
Regional rights and partnering value.While not a product line in the consumer sense, ADC Therapeutics can also monetize its portfolio through territorial licenses, development collaborations, and related agreements. For a smaller biotech, that is an important part of the commercial toolkit because it converts scientific assets into cash without requiring a full global field organization.

There is no real “legacy versus new” split in the way a large pharmaceutical portfolio might have. Instead, the split is between one commercial product that funds the enterprise in part and a pipeline that must prove it can become the next growth layer.

5. What Are the Key Competitors or Peers of ADC Therapeutics?

ADC Therapeutics competes both at the product level and at the platform level. In lymphoma, the most important competition is therapeutic rather than corporate: physicians compare modalities, lines of therapy, toxicity, logistics, and speed to treatment. The closest competitors and peers include:

Roche / Genentech: A major force in B-cell lymphoma through products such as Polivy and Columvi. Roche matters because it competes for the same prescriber attention and treatment-sequencing decisions.
Gilead / Kite: Yescarta is a leading CAR-T therapy in large B-cell lymphoma. It is not directly comparable operationally to Zynlonta, but it competes for patients in later-line treatment pathways.
Bristol Myers Squibb: Breyanzi is another important CAR-T option in large B-cell lymphoma and shapes how physicians think about sequencing non-cell-therapy alternatives.
AbbVie / Genmab: Epkinly is a bispecific antibody that competes strongly for relapsed or refractory diffuse large B-cell lymphoma patients, especially because bispecifics offer an off-the-shelf alternative to cell therapy.
Novartis: Kymriah remains a relevant CAR-T therapy in lymphoma, even if competitive positioning varies by line of therapy and treatment center.
Incyte / MorphoSys: Monjuvi, typically paired with lenalidomide, is another non-cell-therapy option that can matter in physician decision making for certain second-line or later patients.
Pfizer / Seagen: Not the closest direct competitor to Zynlonta in DLBCL, but one of the most important ADC peers because of Seagen’s long-standing capabilities in ADC development, manufacturing, and commercial execution.
AstraZeneca / Daiichi Sankyo: More a platform peer than a direct Zynlonta rival, but highly relevant because it sets the standard for what strong ADC R&D and partnering can look like.

The key point is that ADC Therapeutics is not only competing against other ADC developers. It is competing against multiple oncology modalities that offer very different trade-offs in efficacy, toxicity, logistics, and site-of-care fit.

6. What Is the Marketing Strategy of ADC Therapeutics?

ADC Therapeutics’ marketing strategy is highly targeted and specialist-led. This is not a consumer-health or broad primary-care marketing model. The company’s core audience is hematologists and oncologists who treat aggressive B-cell lymphomas, especially in settings where treatment speed, line of therapy, and patient eligibility constraints affect decision making.

In practice, the company’s marketing appears to rely on five levers:

Clinical-data marketing: congress presentations, publications, and evidence generation are central because oncologists adopt based on data rather than brand familiarity alone.
Key-opinion-leader engagement: specialist oncology brands are built in part through physician advocates, advisory interactions, and visibility in academic forums.
Field-based specialist promotion: a focused commercial team can cover a relatively small universe of high-value treatment centers.
Market-access support: reimbursement services, payer engagement, and patient-support infrastructure are important because oncology buy-and-bill economics influence prescribing behavior.
Partner-led international promotion: outside the U.S., ADC Therapeutics has generally preferred to leverage partners rather than recreate the same specialist model country by country.

Marketing is therefore a supporting capability rather than the company’s main differentiator. The real differentiator, if it exists, has to come from clinical utility and evidence, with marketing making that value legible to prescribers and treatment centers.

7. What Are the Key Customer Segments of ADC Therapeutics?

ADC Therapeutics serves a narrow but economically important set of customer segments.

Community hematology and oncology practices.These providers matter because an off-the-shelf infused therapy can fit community settings differently than CAR-T, which often requires specialized center infrastructure.
Academic cancer centers and hospital-based oncology programs.These institutions influence treatment pathways, publish data, and often treat the most complex relapsed or refractory patients. They are critical for adoption, evidence generation, and thought leadership.
Infusion providers and specialty distributors.These are often the direct commercial counterparties in the channel, even though they are not the clinical decision makers.
Payers and reimbursement stakeholders.Commercial and government payers are not end users, but they are central to access, prior authorization, and provider economics.
Regional commercialization partners.Where ADC Therapeutics licenses rights outside the U.S., the partner becomes a key customer-equivalent relationship because the partner’s performance determines market access, local launch quality, and royalty streams.

The company is not broadly diversified by end market. It remains heavily concentrated in oncology, and more specifically in a relatively small set of aggressive hematologic malignancy treatment settings.

8. What Is the Sales Model of ADC Therapeutics?

ADC Therapeutics uses a specialist biopharma sales model. In the U.S., it sells Zynlonta through a focused commercial organization that calls on hematology-oncology prescribers, treatment centers, and account stakeholders involved in infused oncology therapies. The channel is narrow, but each account can be strategically important because the total addressable prescriber base is far smaller than in primary care.

The practical model appears to work as follows:

Direct U.S. promotion to targeted treatment accounts through a specialist field force and medical affairs team.
Buy-and-bill style provider economics typical of infused oncology drugs, making reimbursement support and account management especially important.
Specialty distribution and logistics rather than mass retail pharmacy channels.
Partner-led sales outside the U.S. where ADC Therapeutics has chosen not to stand up full local commercial teams.

This channel structure affects growth in several ways. It can be capital efficient because the company does not need a massive sales force, but it also means growth depends heavily on field-force productivity, treatment-center penetration, and share of voice in a specialist market. It also creates obvious consulting opportunities in sales-force sizing, account prioritization, provider segmentation, and market-access analytics.

9. In What Geographies Does ADC Therapeutics Operate?

ADC Therapeutics is headquartered in Epalinges, Switzerland and has operated with a transatlantic footprint rather than a purely Swiss one. Its commercial and operational profile is best described as globally connected but U.S.-weighted.

Switzerland: corporate headquarters and an important part of the company’s legal and strategic base.
United States: the most important commercial market, particularly for Zynlonta, as well as a major hub for commercial, medical, and development activities.
United Kingdom and broader Europe: development, management, and partner-facing activities have historically had a meaningful presence here.
International territories through partners: rather than owning a broad direct field presence, the company has sought to reach additional markets through licensing and commercialization agreements.
Global manufacturing footprint through contractors: the company’s production and supply network is international even though it does not own a globally dispersed plant base.

That means ADC Therapeutics is more diversified in operations than in revenue. As of FY2023 and 2024 public updates, its commercial revenue base remained substantially more concentrated than the geographic spread of its scientific, regulatory, and supply activities.

10. Who Are the Owners of ADC Therapeutics?

ADC Therapeutics is a publicly traded company listed on the New York Stock Exchange under the ticker ADCT. As of 2024 public disclosures, it appeared to be broadly held rather than controlled by a single shareholder, family, or government owner. Ownership is primarily institutional and can change meaningfully over time as specialist healthcare investors adjust positions.

Historically, the company’s roots are tied to Auven Therapeutics, which was instrumental in its creation. For current ownership concentrations, the most reliable sources are the latest proxy statement and Schedule 13D or 13G filings. The practical governance point is that ADC Therapeutics operates as a public biotech with board and management oversight rather than as a controlled company.

11. How Is ADC Therapeutics Organized?

ADC Therapeutics is organized more simply than a large pharmaceutical company. Officially, it reports one operating and reportable segment. Practically, the business is organized around functions rather than multiple standalone business units.

Commercial operations: focused largely on Zynlonta in the U.S.
Research and development: discovery, translational science, clinical development, and regulatory affairs for the ADC pipeline.
Technical operations: manufacturing oversight, supply, quality, and chemistry-manufacturing-controls coordination across third parties.
Medical affairs and pharmacovigilance: critical in oncology because post-approval evidence, safety monitoring, and physician education continue after launch.
Corporate functions: finance, legal, partnering, investor relations, and governance.

Its legal structure is that of a Swiss public company with subsidiaries, but economically the company behaves like a focused oncology biotech with one commercial franchise and a pipeline portfolio. That is an important distinction: the reporting structure may be simple, but the real management challenge is balancing present-tense commercial execution with future-tense R&D investment.

12. How Does ADC Therapeutics Operate?

On a day-to-day basis, ADC Therapeutics operates as an asset-light but coordination-heavy biopharmaceutical company. It does not create value by running a large integrated manufacturing empire. Instead, it creates value by discovering or in-licensing promising ADC programs, advancing them through clinical development, overseeing specialized external manufacturing, navigating regulators, and commercializing approved products in selected markets.

The major operating activities include:

Target and candidate selection: choosing tumor antigens and ADC constructs that could produce differentiated efficacy and acceptable toxicity.
Clinical development: running trials, managing investigators, collecting safety and efficacy data, and determining where a program fits in the treatment pathway.
Regulatory execution: maintaining approvals, pursuing expansions, and meeting post-marketing obligations.
Manufacturing and quality oversight: coordinating a complex chain of biologic production, payload handling, conjugation, fill-finish, release testing, and distribution.
Commercial support: educating prescribers, securing reimbursement, maintaining supply, and supporting patient access.

The main operational bottlenecks are typical of small oncology biotechs but especially acute here: slow or costly patient enrollment, manufacturing lead times, safety signal management, and the need to allocate limited capital among competing development priorities.

13. What Are the Growth Opportunities for ADC Therapeutics?

The most plausible growth opportunities for ADC Therapeutics are visible in public materials, though each comes with meaningful constraints.

Zynlonta label expansion and lifecycle management.This is the clearest management-stated opportunity. If confirmatory and combination studies are successful, Zynlonta could move into broader use, earlier use, or more durable guideline positioning in large B-cell lymphoma.
Better penetration of community oncology.An off-the-shelf infused therapy can be attractive in settings where cell therapy logistics are harder to navigate. Improved field execution and account targeting could still expand adoption within the current label.
International expansion through partners.ADC Therapeutics can grow without building a full ex-U.S. commercial infrastructure if partners execute well in their territories. This is economically attractive but partly outside the company’s direct control.
Pipeline value creation from new ADC candidates.Programs such as ADCT-601 offer a route to diversification beyond lymphoma. For investors, success here would matter because it would reduce the company’s dependence on Zynlonta.
Platform monetization through business development.A reasonable external inference is that ADC Therapeutics could create value through more licensing, co-development, or regional-rights transactions if capital markets remain selective.

The constraints are equally important. Competition in lymphoma is intense, confirmatory trials are expensive and slow, safety risk can reset a program’s value quickly, and the company’s balance sheet places real limits on how many growth bets it can fund at once.

14. What Is the History of ADC Therapeutics?

ADC Therapeutics was founded in 2011 by Auven Therapeutics to build an oncology company focused on antibody drug conjugates. Its early identity was that of a science-driven development-stage biotech built around targeted-cancer-therapy technology rather than a commercial drug company.

A major milestone came in 2020, when ADC Therapeutics went public on the New York Stock Exchange. The public listing gave it access to capital at a time when investor interest in oncology and next-generation biologics was strong.

The company’s defining commercial breakthrough came in 2021, when the U.S. Food and Drug Administration approved Zynlonta for certain adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. That approval moved ADC Therapeutics from a pure development story into the more complex reality of being a commercial-stage biotech.

Since then, the company’s history has been shaped by two parallel forces: efforts to broaden and support Zynlonta through additional studies and partnerships, and the challenge of advancing a broader pipeline under tight financial constraints. By 2023 and 2024, portfolio prioritization, safety-related development complexity in certain programs, and cost discipline had become major themes in the company’s evolution.

15. What Are the Key Suppliers to ADC Therapeutics?

Suppliers are strategically important to ADC Therapeutics because ADC manufacturing is specialized and because the company depends heavily on third parties rather than a fully captive production network.

The most important supplier categories are:

Biologic drug-substance manufacturers that produce monoclonal antibodies or related intermediates.
Linker and payload suppliers that provide the highly specialized chemistry underpinning ADC potency.
Conjugation and fill-finish partners responsible for combining antibody and payload, sterile processing, and final product preparation.
Analytical testing and quality providers that support release, stability, and compliance work.
Clinical research organizations and trial-service providers that help run studies across multiple sites and countries.
Specialty logistics providers that handle controlled transport and delivery for clinical and commercial material.

Public disclosures from companies like ADC Therapeutics often emphasize that some of these relationships are single-source or limited-source. That matters strategically because a disruption at even one point in the chain can delay trials, constrain commercial supply, or increase cost of goods.

16. How Does the Supply Chain of ADC Therapeutics Function?

ADC Therapeutics’ supply chain is complex even though the company is relatively small. ADCs require a sequence of tightly controlled manufacturing and logistics steps that are harder to replicate than standard small-molecule production.

At a high level, the chain includes:

Sourcing raw materials and biologic inputs for the antibody and payload components.
Producing the antibody and payload in specialized facilities, often run by different contractors.
Conjugating the antibody and payload under highly controlled conditions to achieve the desired product profile.
Fill-finish and packaging for clinical or commercial use.
Quality testing and batch release before any product can move to trial sites or commercial channels.
Cold-chain or controlled distribution to providers, distributors, or clinical locations.

Supply-chain reliability matters because ADC Therapeutics does not have a broad portfolio to cushion disruption. A delay in manufacturing or release can affect both current revenue and the timelines of clinical programs. For a company at this scale, supply chain is not just a support function; it is a direct determinant of strategic flexibility.

17. What Are the Key Assets of ADC Therapeutics?

For ADC Therapeutics, the most important assets are largely intangible rather than physical.

Zynlonta and its regulatory approvals: the company’s single most important economic asset.
ADC intellectual property and know-how: including payload, linker, conjugation, and development expertise.
Clinical and regulatory data packages: these can be as valuable as patents in shaping future approvals, label expansions, and partnering economics.
Pipeline candidates: especially those with credible paths to differentiation and commercialization.
Partnering relationships and territorial rights: these influence geographic reach and non-dilutive funding potential.
Cash and financing capacity: in a development-heavy biotech, liquidity is a strategic asset, not just a balance-sheet line.

ADC Therapeutics is not especially asset-heavy in the sense of owning vast physical infrastructure. Its barriers to entry are rooted more in scientific capability, regulatory progress, and manufacturing know-how than in owned plants or real estate.

18. What Is the Technology Strategy of ADC Therapeutics?

Technology is central to ADC Therapeutics’ competitiveness because the company is built around a therapeutic modality, not just a single molecule. Its technology strategy is to convert ADC design and development into a repeatable platform capability.

Public materials suggest that this strategy rests on several layers:

Target selection: choosing antigens with enough tumor relevance and accessibility to support targeted delivery.
Payload and linker science: using potent cytotoxic payloads and linker systems that can produce meaningful efficacy while keeping toxicity manageable.
Translational pharmacology: understanding how a construct behaves across tumor types, treatment settings, and patient populations.
Manufacturing reproducibility: ensuring that complex ADCs can be made consistently enough for regulators, clinicians, and commercial supply.

Historically, ADC Therapeutics has been closely associated with pyrrolobenzodiazepine, or PBD, dimer-based ADC technology. The strategic question is whether the company can keep evolving its platform so that it is known not only for one approved product, but for a broader ability to produce clinically relevant ADC candidates. In that sense, technology at ADC Therapeutics is both an internal enabler and the core of the customer offering.

19. What Is the R&D Strategy of ADC Therapeutics?

ADC Therapeutics’ research and development strategy is focused, indication-led, and increasingly disciplined. The company is not trying to build the broadest possible oncology pipeline. Instead, it appears to be prioritizing programs where targeted biology, unmet need, and commercial plausibility overlap.

As of 2023 and 2024 public disclosures, the R&D strategy appears to include:

Protecting and extending the value of Zynlonta through confirmatory, combination, and lifecycle-management studies.
Selecting a manageable number of follow-on ADC assets that could diversify the pipeline without overwhelming the company’s capital base.
Using safety and benefit-risk data aggressively in portfolio decisions, especially after safety-related regulatory complexity affected certain programs.
Balancing hematologic malignancies with selected solid-tumor opportunities where ADCs may offer differentiated delivery of cytotoxic payloads.

This is an R&D strategy shaped by scarcity. Unlike a large pharmaceutical company, ADC Therapeutics cannot afford to run many expensive late-stage bets in parallel. Its scientific ambition therefore has to be filtered through portfolio triage, partnering, and strict go-or-no-go decision making.

20. What Is the Finance Strategy of ADC Therapeutics?

ADC Therapeutics’ finance strategy is best understood as runway management in service of scientific and commercial selectivity. As of FY2023 and 2024 public commentary, the company remained dependent on its balance sheet and external capital rather than self-funded from operations, so preserving liquidity is a strategic necessity.

The main elements of the finance strategy appear to be:

Prioritize spending around the highest-value programs, especially Zynlonta commercialization and the most credible pipeline assets.
Use partnerships to reduce capital needs, particularly in ex-U.S. markets where building direct infrastructure would be expensive.
Maintain flexibility in funding sources, which for companies at this stage can include equity, debt, royalty-linked structures, or milestone-bearing transactions.
Control operating burn, including limiting strategic sprawl across too many development programs.
Reinvest rather than distribute cash, as dividends are not part of the company’s capital-allocation model.

Finance strategy is therefore tightly linked to corporate strategy. If ADC Therapeutics cannot align development ambition with available capital, even scientifically promising assets could become value destructive. Conversely, if it can pair disciplined spend with a handful of meaningful clinical wins, the operating leverage could be significant.

21. How Companies Like ADC Therapeutics Leverage Independent Consultants through Umbrex

Umbrex has built a global community of more than 8,000 independent management consultants based in over 50 countries. These consultants are alumni of McKinsey, Bain, BCG, and other top consulting firms. Companies like ADC Therapeutics use Umbrex when they need high-caliber strategy and execution support without hiring a full consulting team with the associated overhead. For a focused oncology company balancing commercialization, portfolio choices, supply complexity, and financing discipline, that model can be especially useful.

Representative projects Umbrex consultants could support for a company like ADC Therapeutics include:

Zynlonta growth strategy review: assess where Zynlonta can win within the evolving large B-cell lymphoma treatment pathway, including community versus academic setting priorities.
Field-force effectiveness diagnostic: redesign account segmentation, call planning, territory coverage, and key-account management for a narrow hematology-oncology customer base.
Market-access and buy-and-bill economics analysis: identify reimbursement friction points, provider-economics barriers, and patient-access bottlenecks affecting product uptake.
Lifecycle and indication-expansion business case: build integrated commercial and financial models for confirmatory studies and potential label-expansion scenarios.
Portfolio prioritization PMO: create a stage-gate governance process to compare Zynlonta lifecycle investments against pipeline programs such as ADCT-601 and other candidates.
ADC manufacturing and supply-chain risk assessment: map single-source exposure, batch-release bottlenecks, inventory policy, and backup-capacity options across the external network.
Ex-U.S. partnering strategy: evaluate which geographies should be partner-led, what capabilities partners should bring, and how deal structures should balance upfront cash with long-term value.
Competitive war room for lymphoma: track how bispecifics, CAR-T therapies, and other targeted agents are reshaping treatment sequencing and physician behavior.
R&D operating-model redesign: improve decision rights, milestone governance, and resource allocation across clinical development, medical affairs, and technical operations.
Cash-runway and strategic-finance planning: develop scenario models for burn reduction, partnering alternatives, funding options, and capital-allocation trade-offs.